Cocrystal Pharma, Inc.
NASDAQ:COCP
1.73 (USD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 2.014 | 6.564 | 0 | 0 | 0 | 0.078 | 0.009 | 0 | 17.191 | 12.605 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 15.169 | 0.242 | 0.24 | 0.239 | 0.004 | 0.05 | 0.101 | 0.201 | 0.192 | 0.004 | 0.004 | 9.969 | 8.64 | 0.004 | 0.005 | 0.002 | 0.002 |
| Gross Profit
| -15.169 | -0.242 | -0.24 | 1.775 | 6.56 | -0.05 | -0.101 | -0.201 | -0.114 | 0.005 | -0.004 | 7.222 | 3.965 | -0.004 | -0.005 | -0.002 | -0.002 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.881 | 0.999 | 0 | 0 | 0 | -1.462 | 0.548 | 0 | 0.42 | 0.315 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 16.059 | 12.392 | 8.794 | 6.307 | 4.004 | 58.572 | 5.822 | 101.679 | 47.261 | 4.071 | 0.017 | 0.743 | 0.4 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 5.99 | 5.745 | 5.427 | 5.293 | 4.863 | 4.352 | 2.44 | 4.14 | 6.765 | 1.737 | 3.283 | 6.34 | 0 | 0.049 | 0.043 | 0.056 | 0.054 |
| Selling & Marketing Expenses
| 7.372 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.775 | 0 | 0 | 0 | 0 | 0.008 |
| SG&A
| 5.99 | 5.745 | 5.427 | 5.293 | 4.863 | 4.352 | 2.44 | 4.14 | 6.765 | 1.737 | 3.283 | 7.115 | 7.453 | 0.049 | 0.043 | 0.056 | 0.062 |
| Other Expenses
| -18.659 | 0 | 0 | 0 | 0 | 0 | -0.131 | -0.001 | -1.686 | -0.591 | 3.283 | 2 | 7.453 | 0 | 0.001 | 0.003 | 0.062 |
| Operating Expenses
| 3.39 | 18.137 | 14.221 | 11.6 | 8.867 | 62.924 | 8.262 | 105.819 | 54.026 | 5.808 | 3.301 | 9.858 | 7.852 | 0.049 | 0.043 | 0.056 | 0.062 |
| Operating Income
| -18.559 | -38.829 | -14.221 | -9.586 | -48.406 | -62.924 | -8.262 | -105.819 | -53.948 | -5.799 | -3.301 | -2.637 | -3.887 | -0.049 | -0.043 | -0.056 | -0.062 |
| Operating Income Ratio
| 0 | 0 | 0 | -4.76 | -7.374 | 0 | 0 | 0 | -691.641 | -644.333 | 0 | -0.153 | -0.308 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.575 | -0.008 | 0.036 | -0.062 | 0.237 | 0.352 | 0.776 | 1.425 | -11.602 | 5.552 | -4.997 | 0.154 | -0.324 | 0 | 0 | 0.002 | 0.002 |
| Income Before Tax
| -17.984 | -38.837 | -14.185 | -9.648 | -48.169 | -62.63 | -7.493 | -104.268 | -65.37 | -0.151 | -11.64 | -7.965 | -5.454 | -0.048 | -0.041 | -0.053 | -0.059 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -4.79 | -7.338 | 0 | 0 | 0 | -838.077 | -16.778 | 0 | -0.463 | -0.433 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0 | 0.008 | 0.004 | 0.008 | 0.019 | -13.582 | -6.88 | -29.394 | -15.248 | -0.052 | 12.118 | 5.482 | 0.003 | -0.001 | -0.001 | -0.003 | -0.001 |
| Net Income
| -17.984 | -38.845 | -14.189 | -9.656 | -48.188 | -49.048 | -0.613 | -74.874 | -50.122 | -0.099 | -19.622 | -7.965 | -5.457 | -0.048 | -0.041 | -0.053 | -0.059 |
| Net Income Ratio
| 0 | 0 | 0 | -4.794 | -7.341 | 0 | 0 | 0 | -642.59 | -11 | 0 | -0.463 | -0.433 | 0 | 0 | 0 | 0 |
| EPS
| -1.86 | -4.77 | -0.16 | -0.17 | -1.51 | -21.01 | -0.3 | -38.17 | -28.6 | -0.29 | -62 | -45.41 | -35.6 | -0.39 | -0.4 | -0.51 | -0.62 |
| EPS Diluted
| -1.86 | -4.77 | -0.16 | -0.17 | -1.51 | -21.01 | -0.3 | -38.14 | -28.6 | -0.29 | -62 | -45.41 | -35.6 | -0.39 | -0.4 | -0.51 | -0.62 |
| EBITDA
| -20.97 | -17.749 | -14.031 | -9.429 | -2.205 | -63.226 | -9.068 | -107.044 | -43.84 | -11.743 | -3.162 | -2.197 | -3.398 | -0.049 | -0.043 | -0.058 | -0.064 |
| EBITDA Ratio
| 0 | 0 | 0 | -4.682 | -0.336 | 0 | 0 | 0 | -562.051 | -1,304.778 | 0 | -0.128 | -0.27 | 0 | 0 | 0 | 0 |